Results 181 to 190 of about 3,841,835 (347)

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

, 2021
Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh   +3 more
openalex   +1 more source

Rhodamine B Adsorption Efficiency of Biochar Produced Through Co‐Pyrolysis of Municipal Sewage Sludge and Food Waste Mixture Under High‐Temperature Condition

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT With the large‐scale construction of wastewater treatment facilities, the production of municipal sewage sludge continues to rise. This sludge contains substantial amounts of toxic and hazardous substances, and improper disposal may lead to secondary environmental pollution.
He Li, Chang Jiang, Rajendra Prasad Singh, Peiyao Xu, Yizhuo Wang, Haokun Gong   +5 more
wiley   +1 more source

AΙ-Driven Drug Repurposing: Applications and Challenges. [PDF]

Medicines (Basel)
Keramida P, Syrigos NK, Kouvela M, Poulakou G, Charpidou A, Fiste O.   +5 more
europepmc   +1 more source

Drug repurposing

Science, 2020
openaire   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

Arthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen, Lu Zhang, David C. Fajgenbaum   +2 more
wiley   +1 more source

The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis

, 2019
Akbar Ahmad, Juliana de Camargo Vieira, Aline Haas de Mello, Thaís Martins de Lima, Suely Kubo Ariga, Denise Frediani Barbeiro, Hermes Vieira Barbeiro, Bartosz Szczęsny, Gábor Törő, Nadiya Druzhyna, Elisa B. Randi, Michela Marcatti, Tracy Toliver‐Kinsky, András Kiss, Lucas Liaudet, Reinaldo Salomão, Francisco García Soriano, Csaba Szabó   +17 more
openalex   +2 more sources

Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates

, 2023
Megan St. Peters, Chun Hui J. Park, Alyna Turner, Alexandre A. Guerin, Jee Hyun Kim   +4 more
openalex   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Editorial: Opportunities and challenges in drug repurposing. [PDF]

Front Pharmacol
Camps I, Künzel SR, Schubert M, Singh RK.   +3 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source